Werewolf Therapeutics downgraded by Wedbush with a new price target
$HOWL
Biotechnology: Pharmaceutical Preparations
Health Care
Wedbush downgraded Werewolf Therapeutics from Outperform to Neutral and set a new price target of $1.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/19/2025 | $1.00 | Outperform → Neutral | Wedbush |
| 4/3/2024 | $12.00 | Mkt Outperform | JMP Securities |
| 8/24/2023 | $9.00 | Outperform | Wedbush |
| 6/6/2023 | $11.00 → $12.00 | Buy | Jefferies |
| 11/19/2021 | $29.00 → $28.00 | Outperform | SVB Leerink |
| 9/10/2021 | $26.00 | Buy | BofA Securities |
8-K - Werewolf Therapeutics, Inc. (0001785530) (Filer)
144 - Werewolf Therapeutics, Inc. (0001785530) (Subject)
144 - Werewolf Therapeutics, Inc. (0001785530) (Subject)
4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of post-ICI advanced or metastatic cutaneous melanoma patients, with potential best-in-class tolerability profileWTX-330 Phase 1b/2 trial initial data demonstrated additional evidence of antitumor activity and highly favorable tolerability profile, building upon monotherapy activity demonstrated in first-in-human Phase 1 clinical trialAdditional Phase 1/1b data update for WTX-124 and completion of Part A of Phase 1b/2 clinical trial for WTX-330 are both expected in the first half of 2026WTX-1011, Werewolf's first nominated INDUCER™ T cell engager development candidate targeting a
Novel INDUCER™ T Cell Engager Platform designed to mitigate systemic toxicities Sequential dosing of INDUKINE™ molecules in preclinical model showed potent antitumor activity with improved safety First-in-kind real-time pharmacokinetic data in a mouse tumor model confirmed WTX-124 selective activation in tumors, sparing healthy tissue WATERTOWN, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today share
– Update on WTX-124 Phase 1/1b clinical trial interim data and End of Phase 1 meeting with the U.S. Food & Drug Administration (FDA) is expected to be provided later in the fourth quarter of 2025 – – Update on Phase 1b/2 clinical trial of WTX-330 and potential further development plan is expected to be provided later in the fourth quarter of 2025 – – WTX-1011, Company's first INDUCER™ T-cell engager development candidate targeting STEAP1, continues IND-enabling studies – WATERTOWN, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activat
Wedbush downgraded Werewolf Therapeutics from Outperform to Neutral and set a new price target of $1.00
JMP Securities initiated coverage of Werewolf Therapeutics with a rating of Mkt Outperform and set a new price target of $12.00
Wedbush initiated coverage of Werewolf Therapeutics with a rating of Outperform and set a new price target of $9.00
4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
SC 13G/A - Werewolf Therapeutics, Inc. (0001785530) (Subject)
SC 13G/A - Werewolf Therapeutics, Inc. (0001785530) (Subject)
SC 13G/A - Werewolf Therapeutics, Inc. (0001785530) (Subject)
Preliminary data on WTX-124 provide compelling early evidence of dose-dependent biomarker and antitumor activity in patients with advanced or metastatic solid tumors relapsed or refractory to standard of care therapy, including two patients with ongoing unconfirmed partial responses (uPR) in the highest dose tested to date, cohort 4 (12 mg) - Safety data indicate WTX-124 is generally well-tolerated through cohort 4 with no dose limiting toxicities and no indication of vascular leak syndrome (VLS) or other typically severe IL-2-mediated toxicities - Preliminary data support the potential of WTX-124 to be a differentiated next-generation IL-2 compound by showing immune cell activation in the
Interim, first-in-human clinical results from initial monotherapy dose-escalation cohorts in ongoing Phase 1/1b study of WTX-124 including safety and preliminary antitumor activity to be described in poster presentation.Additional posters representing an expansive body of data demonstrating the potential of Werewolf's PREDATOR™ platform and INDUKINE™ product candidates will also be presented.Company to host conference call and webcast to review WTX-124 initial clinical results November 3, 2023, at 8:30 am ET WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the d
WATERTOWN, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced the appointment of Steven Bloom as Chief Business Officer. Mr. Bloom brings more than 35 years of experience in the life sciences industry leading teams in corporate development, commercial planning, corporate affairs, and strategic consulting. "Steve brings deep experience in strategic transactions to Werewolf at this critical tim
WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and immunological diseases, today announced the appointment of Anil Singhal, Ph.D., President and Chief Executive Officer of Trishula Therapeutics, as a member of its board of directors. "I am thrilled to join Werewolf's board of directors as the company advances its novel INDUKINE molecules through clinical development," said Dr. Singhal. "Werewolf is demonstrating the power of the PREDATORTM protein engineering p
WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of novel, conditionally activated INDUKINE™ therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced the appointment of Michael B. Atkins, M.D., to its Board of Directors. "Mike is a world-renowned oncologist and clinical researcher who has made countless contributions to the field of cancer immunotherapy. I am delighted to have Mike join our Board at this important time in the clinical development of our WTX-124 and WTX-330 INDUKINE molecules," sai